|
Post by mango on Nov 6, 2017 23:53:50 GMT -5
1. How so? Every pharma gives out free samples to hook patients. What does MNKD do above and beyond? Al Mann spent nearly a billion dollars of his own money to fund the company in order to ensure things were done the right way. Ethics, morality, commitment, and love. 2. No they don’t. They have a rookie CEO. Their CMO left at a critical time and have yet to replace him. Al Mann is no longer there. MannKind developed the world's first and only inhaled monomeric insulin formulation that also mimics the first-phase insulin response, something both T1D and T2D have loss and need restored or replaced. Afrezza does that. Afrezza also is the world's only insulin that does not produce insulin-derived amyloidosis. Takes some extremely brilliant minds to do what they did. 3. How so more than any other biopharm? No other companies in this space could ever amount to what MannKind is. The BP companies in this space that were around for years before Al showed up, have yet to develop a prandial insulin that restores glucose homeostasis by matching physiologic insulin secretion. These megacorporations have millions of dollars at their disposal and hundreds of employees, yet can not develop something useful and safe because they do not understand what health is, nor do they have the desire to put in the time required to be on MannKind's level. Sanofi did not even possess the scientific expertise and knowledge required to manufacture Afrezza, which is why MannKind opted to so it themselves. They are the only company in the world to do what they have done—and on with their very first insulin formulation taboot. 4. That’s because they don’t have money to do so. That is part of the Al Mann way. Have you ever seen the early 2000's MannKind websites? You'll also notice that the companies they partner with are similar, perhaps for a reason. MannKind science prevails the bullshit. 5. But who was artificial pancrease or countless other medical breakthroughs and 1 minute of google search reveals? Afrezza is just another tool in a diabetics tool box. By no means replaces anything in a disruptive way. Heck, only a small % of diabetics even need prandial insulin. Yes, Al did many amazing things during his lifetime. Afrezza was his biggest endeavor, and he never lost his hope and inspiration. Afrezza restores glucose homeostasis. No other tool in the diabetes tool box restores anything. That is pretty damn significant. 6. This can be achieved in a majority of people with tight diet (I talking strict diet) and exercise. But hey, Americans rather have a magic pill to solve their issues. Diet and exercise cannot restore glucose homeostasis. Diet and exercise cannot restore nor replace the first-phase insulin response which is loss in T1D and T2D. Insulin plays a key role in glucose homeostasis and many other physiological processes. Diet and exercise cannot replace insulin's role in regulating glucose homeostasis. The term "prediabetes" is a nice word someone made up, probably the ADA, and it is merely the early stages of T2D. "Prediabetes" = impaired glucose homeostasis, a result of pancreatic beta cell dysfunction and impaired early-phase insulin response. Your analysis is plagued with bias Maybe. Maybe not.
|
|
|
Post by mytakeonit on Nov 7, 2017 2:24:00 GMT -5
mytakeonit is ... don't respond or quote brew breath ... he is on his own agenda and will pass out shortly when his shortlng fails.
|
|
|
Post by falconquest on Nov 7, 2017 6:08:05 GMT -5
Maybe Mike isn't worried about credibility as he believes 9 mos. down the road investors will be flocking to invest, if he didn't get the alloted raise he managed at the timing it was needed he may not have needed to worry about 9 mos. down the road. It's called survive and advance, rule of nature....obviously there was some significant confidence at $6/sh as a vote of confidence by investors that may not be worried about the current quarters "guidance". As much as SO is harping on "the street" and their possible dismay falling short of guidance, that is a continuing charade of noise over the bigger picture which is getting the insurance on board, that is where the rubber meets the road in this race hey Joey, maybe I missed it, but did we ever hear exactly who the investors were at $6? Over the past 18 months I remember thinking “what if” there were some big pockets, loyal to Al, who wanted to help save MNKD and not let it chocked out by all the evil doers.... throw $100mil at it for 10%...... but of course that would value MNKD at $1B or roughly $10/sh.... hard to justify when it’s been trading at $2, give or take, for the past year,,, and how could they possibly bump the sp up that much that quickly? Well,,,,, I feel like I just saw it happen...... I really don’t care who the new investors are, I just hope it wasn’t a total charity case and that we’re not heading straight back down to depend solely on script numbers. In my mind this is another of those events in the history of Mannkind for which we will never get an answer. " and how could they possibly bump the sp up that much that quickly? " Looking at this from an "agnostic of Mannkind" point of view, how does a company suddenly boost their share price to levels not seen in a couple of years to then make a stock offering right at the time they require funding? To me, the retreat of the share price afterward lends credence to this being a manufactured move. This has never sat well with me and I would like to know the nuts and bolts about how it works.
|
|
|
Post by careful2invest on Nov 7, 2017 6:56:48 GMT -5
hey Joey, maybe I missed it, but did we ever hear exactly who the investors were at $6? Over the past 18 months I remember thinking “what if” there were some big pockets, loyal to Al, who wanted to help save MNKD and not let it chocked out by all the evil doers.... throw $100mil at it for 10%...... but of course that would value MNKD at $1B or roughly $10/sh.... hard to justify when it’s been trading at $2, give or take, for the past year,,, and how could they possibly bump the sp up that much that quickly? Well,,,,, I feel like I just saw it happen...... I really don’t care who the new investors are, I just hope it wasn’t a total charity case and that we’re not heading straight back down to depend solely on script numbers. In my mind this is another of those events in the history of Mannkind for which we will never get an answer. " and how could they possibly bump the sp up that much that quickly? " Looking at this from an "agnostic of Mannkind" point of view, how does a company suddenly boost their share price to levels not seen in a couple of years to then make a stock offering right at the time they require funding? To me, the retreat of the share price afterward lends credence to this being a manufactured move. This has never sat well with me and I would like to know the nuts and bolts about how it works. I agree that "we will never get an answer" to that and many other "events" that occur with this stock. (And most others) That's just the way that todays Wall Street works. Unfortunately, we retail investors are always left in the dark and are at the mercy of the games that the "big guys" play. It's all controlled. In some cases, it's even criminal! Once I saw how Cramer admitted to manipulating stock prices to wherever he wanted them, (And he is certainly not alone) I lost all faith in the credibility of the market! GLTA!
|
|
|
Post by falconquest on Nov 7, 2017 7:18:38 GMT -5
...and that's what bothers me careful, thanks for your comments.
|
|
|
Post by lennymnkd on Nov 7, 2017 7:27:07 GMT -5
But at the end of the day ,good earnings trump even the bad guys !
|
|
|
Post by traderdennis on Nov 7, 2017 9:22:26 GMT -5
IF he misses guidance, I'm sure he will explain his reasoning for missing very well. I believe in the product. Sales growth is continuing at a sustainable pace and will most likely eventually perform well enough to be profitable. It is all about getting the word out to as many diabetics as possible. We shall see tomorrow. Maybe the sales growth from the label change takes more time than he anticipated. Maybe Mike isn't worried about credibility as he believes 9 mos. down the road investors will be flocking to invest, if he didn't get the alloted raise he managed at the timing it was needed he may not have needed to worry about 9 mos. down the road. It's called survive and advance, rule of nature....obviously there was some significant confidence at $6/sh as a vote of confidence by investors that may not be worried about the current quarters "guidance". As much as SO is harping on "the street" and their possible dismay falling short of guidance, that is a continuing charade of noise over the bigger picture which is getting the insurance on board, that is where the rubber meets the road in this race other than the cob no one can say definitely there was a long position taken thru the secondary offering. Until some 13d s come out I think Wall Street lulled a fast one. Sold above 6.50 and covered thru the secondary at 6.
|
|
|
Post by matt on Nov 7, 2017 10:05:02 GMT -5
other than the cob no one can say definitely there was a long position taken thru the secondary offering. Until some 13d s come out I think Wall Street lulled a fast one. Sold above 6.50 and covered thru the secondary at 6. You won't necessarily see that data, not ever. Many investors deliberately cap investments at 4.99% of the outstanding shares which lets them off the hook for filing a 13D. Similarly, most institutional holders only have to disclose once per quarter their holdings on the last day of the quarter, and that not until 45 days after quarter end. It doesn't matter if the institution was long or short, or by how much, on September 29 or October 1; they are only required to report their net position on September 30 and then not again until December 31. A lot of PIPE investors commit to purchase securities from the offering and immediately short the position, delivering the new shares to close off the short. This is entirely legal since the investor has a bona fide economic exposure to hedge the moment they sign the subscription agreement. While some will argue that this is not worth it to simply lock in a 50 cent gain, making small money on a riskless bet over the course of a few days translates to huge percentage gains when repeated enough times over the course of a year and the investors don't need to worry about the fundamentals of the company they are buying; only the size of the discount.
|
|
|
Post by orlon on Nov 7, 2017 12:19:31 GMT -5
I'm just giddy with anticipation and optimism that this will be the best ever CC ever. With all the great things that have been brewing for the the past several years and hoping from CC to CC that we will soon turn the corner, I sincerely believe this is it! I don't understand all the anxiety coming from some...this is going to be great! I can see the PPS jumping big time tomorrow based on great news that until only recently has been kept secret. Good luck to us all.
|
|
|
Post by awesomo on Nov 7, 2017 12:24:33 GMT -5
I'm just giddy with anticipation and optimism that this will be the best ever CC ever. With all the great things that have been brewing for the the past several years and hoping from CC to CC that we will soon turn the corner, I sincerely believe this is it! I don't understand all the anxiety coming from some...this is going to be great! I can see the PPS jumping big time tomorrow based on great news that until only recently has been kept secret. Good luck to us all. You seem miserable, why do you do this to yourself?
|
|
|
Post by orlon on Nov 7, 2017 12:40:36 GMT -5
Miserable? I'm beside myself with joyful optimism:)
|
|
|
Post by dreamboatcruise on Nov 7, 2017 12:54:06 GMT -5
Miserable? I'm beside myself with joyful optimism:) Perhaps he thought it so over the top he assumed you were drinking, which isn't a good sign so early in the day. I assumed you were merely being sarcastic.
|
|
|
Post by mnholdem on Nov 7, 2017 12:59:25 GMT -5
Miserable? I'm beside myself with joyful optimism:) Perhaps he thought it so over the top he assumed you were drinking, which isn't a good sign so early in the day. I assumed you were merely being sarcastic.
|
|
|
Post by mnholdem on Nov 7, 2017 13:54:55 GMT -5
The information SO has been referring to in his articles comes from the recent Prospectus filed by MannKind on 10-11-17 related to the private stock placement:
Financial Update
Although our financial results as of and for the three months ended September 30, 2017 are not yet finalized, the following information reflects our expectations with respect to such results based on currently available information:
• For the three months ended September 30, 2017, we expect to report between $2.6 million and $3.0 million of gross Afrezza product revenue and between $1.8 million and $2.2 million of net Afrezza product revenue.
• We estimate that as of September 30, 2017, our cash and cash equivalents were approximately $20.2 million.
• We estimate that as of September 30, 2017, the principal balance outstanding for our 9.75% Senior Convertible Notes due 2019 and 8.75% Senior Convertible Notes due 2019 issued under our facility agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. was $60.0 million; our 5.75% Convertible Senior Subordinated Exchange Notes Due 2018 was $27.7 million; and our borrowings under our loan arrangement with The Mann Group LLC was $79.7 million.
• We estimate that the annual purchase requirements under the insulin supply agreement with Amphastar as of September 30, 2017 were unchanged from June 30, 2017, except for the impact of foreign currency translation. The Company has not purchased the annual minimum required quantities of insulin for 2017 of €2.7 million.
The preliminary financial results presented above reflect our estimates based solely upon information available to us as of the date of this current report, is not a comprehensive statement of our financial results or position as of or for the three months ended September 30, 2017, and has not been audited, reviewed or compiled by our independent registered public accounting firm, Deloitte & Touche LLP. Accordingly, Deloitte & Touche LLP does not express an opinion or any other form of assurance with respect thereto. Our actual third quarter results may differ materially from these estimates.
|
|
|
Post by slugworth008 on Nov 7, 2017 14:19:36 GMT -5
Perhaps he thought it so over the top he assumed you were drinking, which isn't a good sign so early in the day. I assumed you were merely being sarcastic. Arguably one of the boards best posts ever. IMO
|
|